Cytokine, catabolic enzyme and structural matrix gene expression in synovial fluid following intra-articular administration of triamcinolone acetonide in exercised horses.
Authors: Knych H K, Vidal M A, Chouicha N, Mitchell M, Kass P H
Journal: Equine veterinary journal
Summary
# Editorial Summary Intra-articular triamcinolone acetonide (TA) is routinely used in performance horses to manage joint inflammation, yet the duration and molecular consequences of this practice remain poorly characterised. Knych and colleagues administered a standard 9 mg dose of TA into the radiocarpal joint of eight exercised Thoroughbreds and monitored synovial fluid samples over 49 days using microarray and quantitative PCR to track inflammatory and structural gene expression changes. Whilst drug concentrations became undetectable in plasma within 6 days and synovial fluid within 28 days, the effects on gene expression proved substantially more prolonged—notably, anti-inflammatory genes (annexin type 1, COX-1 and TNF-stimulated gene 6) remained altered, but importantly, collagen and aggrecan gene expression were significantly downregulated even after drug clearance. The downregulation of collagen expression is of particular concern for practitioners, suggesting that whilst TA effectively suppresses inflammation in the short term, repeated or injudicious use may compromise structural matrix integrity through mechanisms persisting well beyond the drug's measurable presence. This finding warrants a more cautious approach to frequency and indication for TA administration, particularly in high-performance horses where matrix degradation could have significant long-term consequences for joint health.
Read the full abstract on PubMed
Practical Takeaways
- •While TA provides short-term anti-inflammatory benefits, the downregulation of collagen gene expression suggests cautious, judicious use is warranted to avoid compromising cartilage integrity with repeated or excessive injections
- •Gene expression effects persist well beyond detectable drug levels (up to 49 days), indicating both prolonged therapeutic and potentially prolonged adverse effects that should inform re-injection timing decisions
- •Synovial fluid sampling can be used clinically to monitor individual joint responses to corticosteroid therapy, potentially guiding personalized treatment protocols
Key Findings
- •5490 genes were significantly altered following intra-articular TA administration, with effects on inflammatory and structural genes persisting beyond detectable drug concentrations (plasma: 6 days, synovial fluid: 28 days)
- •Collagen gene expression was significantly downregulated following TA administration, indicating potential detrimental effects on cartilage matrix
- •Anti-inflammatory genes (annexin type 1, COX-1, TNF-stimulated gene 6) showed significant expression changes correlating with the prolonged effects observed beyond measurable drug concentrations
- •Synovial fluid proved to be an effective biological matrix for studying corticosteroid effects on gene expression in exercised horses